Braveheart Bio, Inc. Common Stock (BRVE) — Cash Flow-to-Debt Ratio
Braveheart Bio, Inc. Common Stock (BRVE) has a Cash Flow-to-Debt Ratio of -0.08x as of June 2026, meaning its operating cash flow of $-16.95 Million could theoretically repay 0% of its total liabilities ($222.86 Million) in one year. See Braveheart Bio, Inc. Common Stock (BRVE) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Braveheart Bio, Inc. Common Stock Cash Flow-to-Debt Ratio (2025–2025)
Historical debt coverage capacity for Braveheart Bio, Inc. Common Stock across 1 annual periods. See Braveheart Bio, Inc. Common Stock (BRVE) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Cash Flow-to-Debt Ratio for Braveheart Bio, Inc. Common Stock (2025–2025)
Year-by-year debt coverage analysis for Braveheart Bio, Inc. Common Stock. For the full cash flow conversion analysis, see Braveheart Bio, Inc. Common Stock cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.01x | $-2.01 Million | $155.22 Million | — |